Beta-blockade and A1-adenosine receptor agonist effects on atrial fibrillatory rate and atrioventricular conduction in patients with atrial fibrillation

Europace

Volumn 16, Issue 4, 2014, Pages 587-594

  Corino, Valentina D A ^a   Holmqvist, Fredrik ^b   Mainardi, Luca T ^a   Platonov, Pyotr G ^b  

^a POLITECNICO DI MILANO   (Italy)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Atrial fibrillation frequency; Irregularity; RR series; Tecadenoson; Variability

Indexed keywords

ADENOSINE A1 RECEPTOR AGONIST; ESMOLOL; TECADENOSON; ADENOSINE; ADENOSINE RECEPTOR STIMULATING AGENT; ANTIARRHYTHMIC AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; FURAN DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ADULT; ARTICLE; ATRIOVENTRICULAR CONDUCTION; BETA ADRENERGIC RECEPTOR BLOCKING; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM FIBRILLATION; HEART RATE VARIABILITY; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; STANDARD; AGED; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; ELECTROCARDIOGRAPHY; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; TIME; TREATMENT OUTCOME;

ADENOSINE; ADMINISTRATION, INTRAVENOUS; ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIOVENTRICULAR NODE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FURANS; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; PURINERGIC P1 RECEPTOR AGONISTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84898843510     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut251     Document Type: Article

References (33)

1. FusterV, Rydén LE,CannomDS, Crijns HJ, Curtis AB, EllenbogenKAet al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2006;8:651-745
2. Stein KM, Borer JS, Hochreiter C, Devereux RB, Kligfield P. Variability of the ventricular response in atrial fibrillation and prognosis in chronic nonischemic mitral regurgitation. Am J Cardiol 1994;74:906-11
3. Langendorf R, Pick A, Katz LN. Ventricular response in atrial fibrillation: Role of concealed conduction in the AV junction. Circulation 1965;32:69-75
4. Toivonen L, Kadish A, KouW, Morady F. Determinants of the ventricular rate during atrial fibrillation. J Am Coll Cardiol 1990;16:1194-200
5. Stein K,Walden J, Lippman N, Lerman B. Ventricular response in atrial fibrillation: Random or deterministic? Am J Physiol 1999;277:H452-8
6. Hayano J, Yamasaki F, Sakata S, Okada A, Mukai S, Fujinami T. Spectral characteristics of ventricular response to atrial fibrillation. Am J Physiol 1997;273:H2811-16
7. Yamada A, Hayano J, Sakata S, Okada A, Mukai S, Ohte N, et al. Reduced ventricular response irregularity is associated with increased mortality in patients with chronic atrial fibrillation. Circulation 2000;102:300-6
8. Platonov PG, Cygankiewicz I, Corino VDA, Mainardi LT, Moss A, Zareba W; MADIT-II trial investigators. Reduced short-Term variability of RR intervals is associated with increased mortality in MADIT-II patients with atrial fibrillation. Eur Heart J 2010;31:719
9. Corino VDA, Cygankiewicz I, Mainardi LT, Vazquez R, Bayes Genis A, Bayes de Luna A, et al. Reduced short-Term variability of RR intervals during atrial fibrillation is associated with increased mortality in patients with congestive heart failure. Heart Rhythm 2012;9:s29
10. Platonov PG, Holmqvist F. Atrial fibrillatory rate and irregularity of ventricular response as predictors of clinical outcome in patients with atrial fibrillation. J Electrocardiol 2011;44:673-7
11. Mangin L, Vinet A, Page P, Glass L. Effects of antiarrhythmic drug therapy on atrioventricular nodal function during atrial fibrillation in humans. Europace 2005;7:S71-82
12. Prystowsky EN, Niazi I, Curtis AB, Wilber DJ, Bahnson T, Ellenbogen K, et al. Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-Adenosine receptor agonist. J Am Coll Cardiol 2003;42:1098-102
13. Snowdy S, LiangHX, Blackburn B,LumR, Nelson M,Wang L, et al.Acomparison of an A1 adenosine receptor agonist (TECADENOSON CVT-510) with diltiazem for slowing of AV nodal conduction in guinea pig. Br J Pharmacol 1999;126:137-46
14. Lerman BB, Ellenbogen KA, Kadish A, Platia E, Stein KM, Markowitz SM, et al. Electrophysiologic effects of a novel selective adenosine A1 agonist (CVT-510) on atrioventricular nodal conduction in humans. J Cardiovasc Pharmacol Ther 2001;6:237-45
15. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: Standards of measurement, physiological interpretation, and clinical use. Circulation 1996;93:1043-65
16. Pincus SM. Approximate entropy as a measure of system complexity. Proc Natl Acad Sci USA 1991;88:2297-301
17. Porta A, Baselli G, Liberati D, Montano N, CogliatiC, Gnecchi-RusconeTet al. Measuring regularity by means of a corrected conditional entropy in sympathetic outflow. Biol Cybern 1998;78:71-8
18. Stridh M, Sörnmo L. Spatiotemporal QRST cancellation techniques for analysis of atrial fibrillation. IEEE Trans Biomed Eng 2001;48:105-11
19. Stridh M, Sörnmo L, Meurling CJ, Olsson SB. Sequential characterization of atrial tachyarrhythmias based on ECG time-frequency analysis. IEEE Trans Biomed Eng 2004;51:100-13
20. CorinoVDA, Cygankiewicz I, Mainardi LT, StridhM, Vasquez R, Bayes de LunaAet al. Association between atrial fibrillatory rate and heart rate variability in patients with atrial fibrillation and congestive heart failure. Ann Noninvasive Electrocardiol 2013;18: 41-50
21. Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O. Termination of acute atrial fibrillation in theWolff-Parkinson-White syndrome by procainamide and propafenone: Importance of atrial fibrillatory cycle length. J Am Coll Cardiol 1990;16: 1408-14
22. Ropella KM, Sahakian AV, Baerman JM, Swiryn S. Effects of procainamide on intra-Atrial electrograms during atrial fibrillation: Implications for detection algorithms. Circulation 1988;77:1047-54
23. Sih HJ, Ropella KM, Swiryn S, Gerstenfeld EP, SahakianAV.Observations from intraatrial recordings on the termination of electrically induced atrial fibrillation in humans. Pacing Clin Electrophysiol 1994;17:1231-42
24. Stambler BS,Wood MA, Ellenbogen KA. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: Electrophysiological determinants of enhanced conversion efficacy. Circulation 1997;96: 4298-306
25. Asano Y, Saito J, Matsumoto K, Kaneko K, Yamamoto T, Uchida M. On the mechanism of termination and perpetuation of atrial fibrillation. Am J Cardiol 1992;69: 1033-8
26. Brugada J, Gursoy S, Brugada P, Atié J, Guiraudon G, Andries E. Cibenzoline transforms random re-entry into ordered re-entry in the atria. Eur Heart J 1993;14: 267-72
27. Holm M, Pehrson S, Ingemansson M, Sörnmo L, Johansson R, Sandhall L, et al. Non-invasive assessment of the atrial cycle length during atrial fibrillation in man: Introducing, validating and illustrating a new ECG method. Cardiovasc Res 1998;38: 69-81
28. Bollmann A, Kanuru NK, McTeague K, Walter PF, DeLurgio DB, Langberg JJ. Frequency analysis human atrial fibrillation using the surface electrocardiogram and its response to ibutilide. Am J Cardiol 1998;81:1439-45
29. Meurling CJ, Ingemansson MP, Roijer A, Carlson J, Lindholm CJ, Smideberg B, et al. Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil. Europace 1999;1:234-41
30. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2012, doi: 10.1002/14651858.CD005049. pub3
31. Hilleman DE, Reyes AP, Mooss AN, Packard KA. Esmolol versus diltiazem in atrial fibrillation following coronary artery bypass graft surgery. Curr Med Res Opin 2003; 19:376-82
32. Sticherling C, Tada H, HsuW, BaresAC, Oral H, Pelosi F, et al. Effects of diltiazemand esmolol on cycle length and spontaneous conversion of atrial fibrillation. J Cardiovasc Pharmacol Ther 2002;7:81-8
33. Nakai T,Watanabe I, Kunimoto S, Kojima T, Kondo K, Saito S, et al. Electrophysiological effect of adenosine triphosphate and adenosine on atrial and ventricular action potential duration in humans. Jpn Circ J 2000;64:430-5.